Limits...
Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?

Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, Doosti M - PLoS ONE (2015)

Bottom Line: Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001).Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD.Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

No MeSH data available.


Related in: MedlinePlus

a) Graphic representation of the plasma levels of CTRP1 in NAFLD, T2DM and NAFLD+T2DM patients in comparison with control group.P-values were obtained by ANOVA and bars represent mean ± 95% confidence intervals. # represent p<0.0001. b) dual-axis representation for differences of CTRP1 and HOMA-IR between NAFLD, T2DM, NAFLD+T2DM, and healthy subjects. (Dashed lines represent HOMA-IR values while the non-dashed lines stand for CTRP1).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4358971&req=5

pone.0118650.g001: a) Graphic representation of the plasma levels of CTRP1 in NAFLD, T2DM and NAFLD+T2DM patients in comparison with control group.P-values were obtained by ANOVA and bars represent mean ± 95% confidence intervals. # represent p<0.0001. b) dual-axis representation for differences of CTRP1 and HOMA-IR between NAFLD, T2DM, NAFLD+T2DM, and healthy subjects. (Dashed lines represent HOMA-IR values while the non-dashed lines stand for CTRP1).

Mentions: Fig. 1 describes the mean value of plasma CTRP1 and HOMA-IR among the study groups. Mean plasma concentration of CTRP1 is significantly different in the overall comparison of all four groups (p<0.0001). In comparison to control group, NAFLD group had higher plasma level of CTRP1 (p<0.0001), T2DM group showed higher plasma level of CTRP1 than NAFLD group (p<0.0001) and the difference (p<0.0001) in CTRP1 level between NAFLD+T2DM group and healthy controls was even greater compared to the two latter groups (fold change increase in NAFLD+T2DM = 1.48, fold change increase in NAFLD = 1.205; Fig. 1a). However, for HOMA-IR, only healthy subjects showed significant (p<0.001) lower levels than patients. No significant difference was observed between patients groups regarding HOMA-IR (Fig. 1b). Since there was a significant difference between healthy subjects and patients regarding HOMA-IR and BMI, we conducted ANCOVA to remove their effects from the observed difference of CTRP1 which showed us significant CTRP1 difference (p<0.0001) between groups even after removing HOMA-IR and BMI variance (S1 Table). Actually no significant differences were observed regarding the interaction of status (groups) × HOMA-IR or status × BMI. Furthermore, considering the close association between NAFLD and MetS, we categorized subjects into two groups: with and without MetS. CTRP1 was significantly (p<0.001) higher in MetS patients compared to healthy individuals. Thus, we carried out adjustment for possible effect of MetS on circulating level of CTRP1 in all studied groups (S2 Table). After removing the effects of MetS, the aforesaid differences between groups regarding CTRP1 were significant (p<0.001). We also performed adjustment for the effects of antihypertensive and anti-diabetic medications on levels of CTRP1 in four studied group separately (S3 Table). After adjusting for medications, significant differences remained in all four groups.


Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?

Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, Doosti M - PLoS ONE (2015)

a) Graphic representation of the plasma levels of CTRP1 in NAFLD, T2DM and NAFLD+T2DM patients in comparison with control group.P-values were obtained by ANOVA and bars represent mean ± 95% confidence intervals. # represent p<0.0001. b) dual-axis representation for differences of CTRP1 and HOMA-IR between NAFLD, T2DM, NAFLD+T2DM, and healthy subjects. (Dashed lines represent HOMA-IR values while the non-dashed lines stand for CTRP1).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4358971&req=5

pone.0118650.g001: a) Graphic representation of the plasma levels of CTRP1 in NAFLD, T2DM and NAFLD+T2DM patients in comparison with control group.P-values were obtained by ANOVA and bars represent mean ± 95% confidence intervals. # represent p<0.0001. b) dual-axis representation for differences of CTRP1 and HOMA-IR between NAFLD, T2DM, NAFLD+T2DM, and healthy subjects. (Dashed lines represent HOMA-IR values while the non-dashed lines stand for CTRP1).
Mentions: Fig. 1 describes the mean value of plasma CTRP1 and HOMA-IR among the study groups. Mean plasma concentration of CTRP1 is significantly different in the overall comparison of all four groups (p<0.0001). In comparison to control group, NAFLD group had higher plasma level of CTRP1 (p<0.0001), T2DM group showed higher plasma level of CTRP1 than NAFLD group (p<0.0001) and the difference (p<0.0001) in CTRP1 level between NAFLD+T2DM group and healthy controls was even greater compared to the two latter groups (fold change increase in NAFLD+T2DM = 1.48, fold change increase in NAFLD = 1.205; Fig. 1a). However, for HOMA-IR, only healthy subjects showed significant (p<0.001) lower levels than patients. No significant difference was observed between patients groups regarding HOMA-IR (Fig. 1b). Since there was a significant difference between healthy subjects and patients regarding HOMA-IR and BMI, we conducted ANCOVA to remove their effects from the observed difference of CTRP1 which showed us significant CTRP1 difference (p<0.0001) between groups even after removing HOMA-IR and BMI variance (S1 Table). Actually no significant differences were observed regarding the interaction of status (groups) × HOMA-IR or status × BMI. Furthermore, considering the close association between NAFLD and MetS, we categorized subjects into two groups: with and without MetS. CTRP1 was significantly (p<0.001) higher in MetS patients compared to healthy individuals. Thus, we carried out adjustment for possible effect of MetS on circulating level of CTRP1 in all studied groups (S2 Table). After removing the effects of MetS, the aforesaid differences between groups regarding CTRP1 were significant (p<0.001). We also performed adjustment for the effects of antihypertensive and anti-diabetic medications on levels of CTRP1 in four studied group separately (S3 Table). After adjusting for medications, significant differences remained in all four groups.

Bottom Line: Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001).Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD.Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

No MeSH data available.


Related in: MedlinePlus